Health Optimization Index
Hormone Replacement Therapy (HRT)
- Nick’s assessment
- Promising
- Research evidence
- A, strong evidence
- Attention
- 11.8 / 100▼ Falling this week
BioHarmony score
Hormone replacement therapy restores estrogen, progestogen, and testosterone to treat menopausal symptoms, cutting hot flash frequency by roughly 75 percent in randomized trials and lowering fracture risk, with the benefit-risk balance most favorable when therapy begins before age 60 or within ten years of menopause.
Surfaced from industry newsletters. It enters at Experimental until the evidence is graded.
Read Nick’s assessment Why it earned this rating
At , HRT lands in the worth-trying band because it is a genuinely effective, exceptionally well-evidenced therapy whose risks are real but largely confined to identifiable groups and manageable through route and candidate selection. The practical verdict is that for a symptomatic woman within roughly ten years of menopause, modern transdermal HRT is a strong and reasonable choice, while for late initiators, women with hormone-sensitive-cancer or clotting histories, and anyone seeking it purely for chronic-disease prevention, the balance tips unfavorable. The score reflects an all-comers assessment; for a well-selected candidate the effective value is higher, and for a poorly selected one it is lower. The North American Menopause Society statement and the Endocrine Society guideline both support this individualized framing.
✅ Best for: Symptomatic perimenopausal and early-postmenopausal women within ten years of their final period who want relief from hot flashes and night sweats; women with genitourinary syndrome of menopause, who often do best with low-dose vaginal estrogen; women with early or surgical menopause, who generally need replacement to at least the natural age of menopause; women at elevated fracture risk who are already using HRT for symptoms and gain bone protection as a bonus; women with distressing low libido, for whom added low-dose testosterone improves desire per the testosterone for women meta-analysis; and hypogonadal men who are not seeking fertility, for whom replacement improves libido, mood, and bone with reassuring cardiovascular safety in the TRAVERSE trial.
❌ Avoid if: You have current or past estrogen-receptor-positive breast cancer, since replacement can feed hormone-sensitive tumors; you have a history of venous thromboembolism or a known thrombophilia, where estrogen compounds clotting risk, especially by the oral route; you have had a recent stroke or heart attack, where the arterial risk outweighs benefit; you have undiagnosed abnormal vaginal bleeding, which must be evaluated before starting; you have active liver disease; you are or might be pregnant; and men who want to preserve fertility should avoid testosterone replacement, which suppresses sperm production as shown in the testosterone trials in older men. Starting systemic HRT de novo many years after menopause also carries an unfavorable balance per the Cochrane cardiovascular review.
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →